(Updates with CBFA confirmation)
BRUSSELS (Thomson Financial) - Belgian financial markets regulator CBFA said
pharmaceuticals group Solvay SA. has bid 6.50 euros per share for biotechnology
group Innogenetics NV.
The news confirms earlier information from a source.
Shares of Innogenetics were suspended before the market opened on Wednesday
pending information on the company, the CBFA said.
Gen-Probe Inc. made a 215 million euros bid for Innogenetics at the
beginning of last month, offering 6.10 euros per share to form the world's
largest standalone molecular diagnosis company.
Solvay had offered 177.6 million euros or 5.75 euros per share at the end of
April.
simon.zekaria@thomsonreuters.com
sz/ak/sz/ak
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|